 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...8485868788899091929394...123124» |
- Avastin (bevacizumab) / Roche, Nexavar (sorafenib) / Bayer, Amgen, Tecentriq (atezolizumab) / Roche
[VIRTUAL] The comparative efficacy of atezolizumab and bevacizumab versus lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC). () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4309;
The results of this NMA suggest that the benefit of atezo+bev is not statistically significant compared to lenvatinib, as the differences between atezo+bev and lenvatinib fell within the Bayesian range of equivalence (upper limit of Crl ≥ 1 for OS and PFS) and were subject to a high degree of uncertainty . The results of the NMA were consistent for all the publicly available data cuts from IMbrave150.
- Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm, Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] Sintilimab plus anlotinib as first-line therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC). () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4305;
P2
Multi-targeted antiangiogenic TKIs, such as lenvatinib and sorafenib, are approved for 1st-line treatment of aHCC . The combination of sintilimab and anlotinib showed promising clinical activities with manageable toxicity for first line treatment of aHCC.
- Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Radiological response as a predictor of pathological response to combined tyrosine kinase inhibitor (TKI) and anti-PD-1 antibodies in hepatocellular carcinoma (HCC). () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4304;
Therefore, imaging evaluation may be used to predict a pathological response and further guide clinical treatment decisions . Response rates (n=23).
- lenvatinib / Generic mfg.
[VIRTUAL] Impact of lenvatinib (LEN) dose-intensity and starting dose on survival among patients with advanced hepatocellular carcinoma (HCC): Results from a Canadian multicenter database (HCC CHORD). () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4302;
In HCC patients starting LEN at a reduced dose does not appear to compromise survival . LEN dose-intensity of > 66.7% was associated with improved survival, but not after controlling for potential confounders.
- Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] Lenvatinib plus pembrolizumab versus lenvatinib in patients with unresectable hepatocellular carcinoma: A real world study. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4298;
LEN dose-intensity of > 66.7% was associated with improved survival, but not after controlling for potential confounders. LEN plus PEMBRO provides significantly better ORR, DCR and PFS then LEN monotherapy for patients with unresectable HCC.
- lenvatinib / Generic mfg.
[VIRTUAL] Real-world effectiveness of lenvatinib monotherapy among previously treated unresectable hepatocellular carcinoma patients in United States clinical practices. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4289;
LEN plus PEMBRO provides significantly better ORR, DCR and PFS then LEN monotherapy for patients with unresectable HCC. Results from this retrospective real-world study affirm the clinical effectiveness of lenvatinib monotherapy among previously treated uHCC patients, including those with prior immunotherapy.
- Tyvyt (sintilimab) / Eli Lilly, Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] A retrospective study on the efficacy and safety of sorafenib or lenvatinib combined with sintilimab in patients with advanced hepatocellular carcinoma. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4287;
Sorafenib or lenvatinib combined with sintilimab showed a good efficacy and safety in patients with advanced hepatocellular carcinoma, the safety and tolerability profiles were consistent with those previously observed . Sorafenib plus sintilimab provided an improved PFS versus lenvatinib, which requires a large sample of randomized controlled trial to confirm.
- Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] Triple combination therapy comprising angiogenesis inhibitors, anti-PD-1 antibodies, and hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4284;
TRAEs were acceptable, and long-term efficacy is reasonably expected . Summary of efficacy outcomes (n = 25).
- AiRuiKa (camrelizumab) / Incyte, Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] A real-world study of camrelizumab in the treatment of hepatocellular carcinoma. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4281;
Between Mar 12, 2020, and Dec 25, 2020, 63 patients were screened for eligibility, of whom 41 eligible patients received camrelizumab were recruited and among whom 15 received apatinib, 16 received lenvatinib, 2 received sorafenib and 1 received regorafenib . Camrelizumab showed promising efficacy and safety in pretreated Chinese patients with advanced hepatocellular carcinoma, and might represent a new treatment option for these patients.
- lenvatinib / Generic mfg.
[VIRTUAL] Impact of bodyweight (BW)-based starting doses on safety and efficacy of lenvatinib (LEN) in patients (pts) with hepatocellular carcinoma (HCC). () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4279;
P1/2, P3
The safety profile was favorable in pts <60 kg who received LEN 8 mg in REFLECT vs those who received LEN 12 mg in Study 202 . Fewer serious TRAEs and dose reductions due to TRAEs were observed in pts with lower BW who received the LEN 8 mg starting dose in REFLECT .
- lenvatinib / Generic mfg.
[VIRTUAL] A multicenter observational study of lenvatinib for unresectable hepatocellular carcinoma in Japan. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4278;
Fewer serious TRAEs and dose reductions due to TRAEs were observed in pts with lower BW who received the LEN 8 mg starting dose in REFLECT . The incidence of TRAEs leading to discontinuation of lenvatinib tended to be higher than in phase 3 REFLECT trials (19.7%), but the safety profile and effectiveness findings for lenvatinib in this study were consistent with previous reports.
- AiRuiKa (camrelizumab) / Incyte, Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] Camrelizumab in combination with TACE for the treatment of unresectable hepatocellular carcinoma (HCC): A multicenter, single-arm, prospective real-world study. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4274;
Q2W or Q3W) with or without antiangiogenic therapy (apatinib, lenvatinib, sorafenib, or regorafenib) at any stage of the TACE treatment . The treatment strategy of TACE in combination with camrelizumab with or without antiangiogenic therapy showed encouraging clinical efficacy and manageable toxicity profile in treating unresectable HCC, which provided a new treatment option for HCC.
- AiTan (rivoceranib) / HLB Bio Group, Balversa (erdafitinib) / J&J, Otsuka
[VIRTUAL] Genomic profiling by cell-free circulating tumor DNA in patients with recurrent adenoid cystic carcinoma (ACC) and the potential activity of selective fibroblast growth factor receptor (FGFR) inhibitors. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_3992;
ctDNA can reveal additional therapeutic targets not present on tNGS and can be repeated serially . FGFR genomic abnormalities can be a driver mutation in patients with refractory advanced ACC and the activity of Erdafinib should be evaluated in this subset of patients with few therapeutic options.
- ||| Nexavar (sorafenib) / Bayer, Amgen
Clinical, P3 data, Journal: REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. (Pubmed Central) - Apr 29, 2021
P3
The efficacy and safety of LEN in the Japanese population were similar to those in the overall population of REFLECT. With manageable adverse events, LEN is a new treatment option for Japanese patients with uHCC.
- |||| Nexavar (sorafenib) / Bayer, Amgen
.@docamitgs, of @UTSWNews, discusses the utility of frontline lenvatinib and sorafenib in hepatocellular carcinoma #hpbcsm https://t.co/hVcIoMh6LY (Twitter) - Apr 29, 2021
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P3 trial, Metastases: LEAP-001 China Extension: Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study (clinicaltrials.gov) - Apr 28, 2021
P3, N=875, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: MK-3475-A70: Pembrolizumab and Lenvatinib in Advanced Cervical Cancer (clinicaltrials.gov) - Apr 28, 2021
P2, N=35, Not yet recruiting, Sponsor: Georgetown University
- Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] A phase II study to evaluate the safety and efficacy of OQL011 on VEGFR inhibitor-associated hand-foot-skin reaction in cancer patients. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_3470;
P2
Clinical Trial Registry Number: NCT04088318 Funding: OnQuality Pharmaceuticals (USA) LLC Background: Hand-Foot Skin Reaction (HFSR) is frequently associated with the use of multi-targeted tyrosine kinase inhibitors of the vascular endothelial growth factor receptor (VEGFRi) such as cabozantinib, regorafenib, sunitinib, and lenvatinib...The correlation between IGA, NCI CTCAE v5.0 for PPE, and patient reported outcomes including Visual Analog Scale of Pain, Hand-foot Quality of Life questionnaire will also be evaluated . This study began enrolling patients in December 2019 and is ongoing.
- BI 836880 / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim, Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] Phase Ib study of BI 836880 (VEGF/Ang2 nanobody) plus ezabenlimab (BI 754091; anti-PD-1 antibody) in patients (pts) with solid tumors. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2636;
P1
BI 836880 plus ezabenlimab had a manageable safety profile . The combination showed preliminary antitumor activity in a range of tumor types.
- [VIRTUAL] Encorafenib and binimetinib with or without nivolumab in treating patients with metastatic radioiodine refractory BRAF V600 mutant thyroid cancer. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2540;
P2
The trial design includes continuous toxicity monitoring with a Pocock-type stopping boundary . This clinical trial is in progress and 3 patients have been enrolled.
- Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] Radiomics-based prediction of response to multikinase inhibitors in radioiodine-refractory differentiated thyroid cancer patients. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2532;
Radiomics technique has the potential to enable clinicians to anticipate the probability of response to TKIs at baseline, directing toward the most suitable patient-tailored therapeutic path . Prospective studies may further validate these preliminary findings.
- lenvatinib / Generic mfg.
[VIRTUAL] Planned drug holiday in a cohort study exploring the effect of lenvatinib on differentiated thyroid cancer. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2525;
Planned drug holiday for lenvatinib demonstrated significantly better clinical outcomes, including TTF, TFS and PFS, than daily oral administration . These data further support use of a planned drug holiday in RAI-refractory DTC patients receiving lenvatinib.
- Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: Results from the phase 3 COSMIC-311 trial. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2449;
P3
C showed a clinically and statistically significant improvement in PFS over P in pts with RAI-refractory DTC after prior VEGFR-targeted therapy with no unexpected toxicities . C may represent a new standard of care in pts with previously treated DTC.
- Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2391;
P2
In pts with previously treated advanced non–MSI-H/pMMR colorectal cancer, lenvatinib plus pembro demonstrated promising antitumor activity and a manageable safety profile . Enrollment in the colorectal cohort was expanded to 100 pts.
- Inlyta (axitinib) / Pfizer, Bavencio (avelumab) / EMD Serono, Pfizer
[VIRTUAL] A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient (MMR-P) recurrent or persistent endometrial cancer (EC). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2223;
P1b/2, P2
This is a two-stage design in the method of Sill et al, with 16 participants anticipated in stage 1 and 19 participants in stage 2, for a total of 35 participants . Accrual is ongoing.
- Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] ENGOT-en11/GOG-3053/KEYNOTE-B21: Phase 3 study of pembrolizumab or placebo in combination with adjuvant chemotherapy with/without radiotherapy in patients with newly diagnosed high-risk endometrial cancer. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2222;
P3
Clinical Trial Registry Number: NCT04634877 Funding: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA Background: Pembrolizumab, a selective humanized anti–PD-1 monoclonal antibody, has demonstrated activity in patients with previously treated mismatch repair (MMR) deficient (dMMR; 57.1% ORR as monotherapy and 63.6% ORR as combination therapy with lenvatinib) and MMR proficient (pMMR; 36.2% ORR as combination therapy with lenvatinib) endometrial cancer (EC)...In total, ̃990 patients are randomized to receive pembrolizumab 200 mg or placebo Q3W for 6 cycles + chemotherapy (carboplatin area under the curve [AUC] 5 or 6 + paclitaxel 175 mg/m2 Q3W or carboplatin AUC 2 or 2.7 + paclitaxel 60 mg/m2 QW) in stage 1...At the investigator’s discretion, radiotherapy (external beam radiotherapy [EBRT] and/or brachytherapy) ± radiosensitizing cisplatin 50 mg/m2 (days 1 and 29) may be administered after completion of chemotherapy...Secondary endpoints include DFS (per blinded independent central review), DFS (per investigator assessment) and OS by biomarker status (PD-L1 and tumor mutational burden), safety (per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0) and quality of life (per European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 [EORTC QLQ-C30] and Endometrial Cancer Module [EORTC QLQ-EN24]) . The study began enrollment in December 2020.
- Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] Health-related quality of life (HRQoL) in advanced endometrial cancer (aEC) patients (pts) treated with lenvatinib plus pembrolizumab or treatment of physician’s choice (TPC). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2186;
P3
No significant differences were observed in HRQoL scores between treatment groups . With no standard treatment approach following failure of platinum-based therapy, these data along with previously reported efficacy and safety findings from Study 309/KEYNOTE-775 further support that L+P has an overall favorable benefit/risk profile compared to chemotherapy.
- Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] KEYNOTE-B61: Open-label phase 2 study of pembrolizumab in combination with lenvatinib as first-line treatment for non-clear cell renal cell carcinoma (nccRCC). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2107;
P2, P3
Secondary efficacy end points for this study are clinical benefit rate, disease control rate, duration of response, progression-free survival, overall survival, and safety . Tertiary/exploratory end points are biomarker analysis and association with clinical response/disease etiopathogenesis.
- [VIRTUAL] A phase 1b/2 umbrella study of investigational immune and targeted combination therapies as first-line therapy for patients with advanced renal cell carcinoma (RCC). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2106;
P1b/2, P3
Coprimary end points are safety and tolerability, establishing the RP2D during the safety lead-in phase (if applicable) and objective response rate per RECIST v1.1 by blinded independent central review (BICR) during the efficacy phase . Secondary end points during the efficacy phase are duration of response, progression-free survival and clinical benefit rate per RECIST v1.1 (BICR), and overall survival.
- Sutent (sunitinib) / Pfizer
[VIRTUAL] Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (LEN) + everolimus (EVE) versus sunitinib (SUN) treatment arms. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2074;
P3
In the CLEAR study, LEN + EVE met the primary endpoint of a significant benefit in PFS vs SUN . The results of these exploratory analyses suggest that subsequent systemic anticancer therapy affected the OS outcome results for LEN + EVE vs SUN in the CLEAR study.
- Keytruda (pembrolizumab) / Merck (MSD), Sutent (sunitinib) / Pfizer
[VIRTUAL] Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): Depth of response and efficacy for selected subgroups in the lenvatinib (LEN) + pembrolizumab (PEMBRO) and sunitinib (SUN) treatment arms. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2072;
P3
In pts with target kidney lesions, LEN + PEMBRO conferred survival benefits vs SUN similar to benefits observed in the overall population . Overall, pts treated with LEN + PEMBRO who had greater than 75% reduction in target lesions had similar OS rates to pts with CR.
- Inlyta (axitinib) / Pfizer, Bavencio (avelumab) / EMD Serono, Pfizer, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] Outcomes of patients who progressed while receiving avelumab + axitinib (A + Ax) and received subsequent treatment (Tx) in JAVELIN Renal 101. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2025;
P3
The most common 2L SA was cabozantinib (60/163), and the most frequent 2L CT was everolimus + lenvatinib (12/41)... In patients with aRCC who received 2L CT following 1L treatment with A + Ax, long-term OS and PFS2 were observed.
- Keytruda (pembrolizumab) / Merck (MSD), Sutent (sunitinib) / Pfizer
[VIRTUAL] Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2005;
P3
In patients with aRCC who received 2L CT following 1L treatment with A + Ax, long-term OS and PFS2 were observed. Compared with SUN, pts in LEN + PEMBRO group had similar or better symptoms and HRQoL.
- Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1807;
P2
The safety profile was consistent with prior studies of len + pembro . These data support len + pembro as a potential regimen for this population of high unmet need.
- Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] CaboRISE: A phase II study evaluating reduced starting dose and dose escalation of cabozantinib as second-line therapy for advanced HCC in patients with compensated liver cirrhosis. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1575;
P2
The CaboRISE trial is an open-label, single arm, multicenter phase II trial, including patients with advanced stage hepatocellular carcinoma (HCC) with compensated liver cirrhosis (Child-Pugh A) in second line treatment, after first line treatment with sorafenib or lenvatinib...By February 2021, 7 centers across Germany have been initiated and a total of 4 out of 40 planned patients have been enrolled . The study is currently ongoing.
- lenvatinib / Generic mfg.
[VIRTUAL] Plasma biomarker study of lenvatinib in gastroenteropancreatic neuroendocrine tumors reveals Ang2 and FGF2 as predictors of treatment response: Results from the international phase II TALENT trial (GETNE 1509). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1525;
In antiangiogenic-pretreated patients, Ang2 and VEGFR2 levels significantly predict response to treatment in panNETs . Importantly, current studies with MKIs should confirm the value of these markers for advanced NETs not only to predict response, but also to stablish sequential treatment options for these patients.
- Opdivo (nivolumab) / Ono Pharma, BMS, Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] Comparative effectiveness of sorafenib, lenvatinib, and nivolumab as first-line systemic therapy for patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis treated at VA Medical Centers. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1514;
Importantly, current studies with MKIs should confirm the value of these markers for advanced NETs not only to predict response, but also to stablish sequential treatment options for these patients. Among patients with HCC and CP class B cirrhosis undergoing first systemic therapy, nivolumab was associated with significantly lower hazard of death compared to sorafenib after adjusting for important covariates.
- Opdivo (nivolumab) / Ono Pharma, BMS, cadonilimab (AK104) / Akesobio
[VIRTUAL] Phase 2 study of AK104 (PD-1/CTLA-4 bispecific antibody) plus lenvatinib as first-line treatment of unresectable hepatocellular carcinoma. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1513;
P1/2
Toxicities were manageable, with no unexpected safety signals . Enrollment for AK104 15 mg/kg q3w plus lenvatinib is currently ongoing, and longer follow-up is needed to further evaluate the durability of response.
- Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1512;
The signature was validated in patients with other solid cancer types, where it retained its predictive ability . Of note, the signature was not able to identify responders among HCC patients that were treated with TKIs prior to anti-PD1 therapy .
- Tuoyi (toripalimab) / Shanghai Junshi Biosci, Coherus
[VIRTUAL] Lenvatinib plus toripalimab as first-line treatment for advanced intrahepatic cholangiocarcinoma: A single-arm, phase 2 trial. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1511;
P2
As the first-line therapy, lenvatinib plus toripalimab provided promising efficacy with reasonable safety profile in advanced ICC patients . It offered an alternative treatment for advanced ICC who cannot tolerate gemcitabine-based chemotherapy.
- Avastin (bevacizumab) / Roche, Nexavar (sorafenib) / Bayer, Amgen, Tecentriq (atezolizumab) / Roche
[VIRTUAL] The cost effectiveness of lenvatinib versus atezolizumab and bevacizumab or sorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in Canada. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1510;
It offered an alternative treatment for advanced ICC who cannot tolerate gemcitabine-based chemotherapy. Results of this analysis demonstrate that lenvatinib represents the optimal use of healthcare resources as a first-line treatment for uHCC in Canada.
- Tuoyi (toripalimab) / Shanghai Junshi Biosci, Coherus
[VIRTUAL] Gemox chemotherapy in combination with anti-PD1 antibody toripalimab and lenvatinib as first-line treatment for advanced intrahepatic cholangiocarcinoma: A phase 2 clinical trial. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1506;
P2
Gemox chemotherapy in combination with Anti-PD1 antibody Toripalimab and Lenvatinib provided remarkable efficacy with reasonable tolerability in advanced ICC patients . These findings warrant further validation in a large randomized clinical trial.
- Keytruda (pembrolizumab) / Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] Exploratory circulating biomarker analyses: lenvatinib + pembrolizumab (L + P) in a phase 1b trial in unresectable hepatocellular carcinoma (uHCC). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1496;
P1b
Changes in serum biomarkers associated with angiogenic-, FGF-, and IFNγ-signaling pathways indicated target engagement of L + P . Decreases in TIMP1 and increases in MCP1 were associated with MTS and OR .
- Tuoyi (toripalimab) / Shanghai Junshi Biosci, Coherus
[VIRTUAL] A phase II trial of lenvatinib plus toripalimab and hepatic arterial infusion chemotherapy as a first-line treatment for advanced hepatocellular carcinoma (LTHAIC study). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1495;
P2
Combination treatment with lenvatinib and toripalimab plus HAIC showed promising antitumor activity and manageable toxicity in patients with advanced HCC . Further randomized, controlled trials are warranted to validate our findings.
- Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP-005 study. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1492;
P2
Lenvatinib plus pembrolizumab demonstrated encouraging efficacy and manageable toxicity in patients with advanced BTC who had received 1 line of prior therapy . Based on these data, enrollment in the BTC cohort has been expanded to 100 patients.
- Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the gastric cancer cohort. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1444;
P2
In patients with advanced gastric cancer who received 2 prior lines of therapy, lenvatinib plus pembrolizumab demonstrated promising antitumor activity and a manageable safety profile . Based on these data, enrollment in the gastric cancer cohort has been expanded to 100 patients.
- || lenvatinib / Generic mfg.
Clinical, Observational data, Retrospective data, Journal: Liver Function in Older Patients With Unresectable Hepatocellular Carcinoma After Administration of Lenvatinib. (Pubmed Central) - Apr 28, 2021
Based on these data, enrollment in the gastric cancer cohort has been expanded to 100 patients. Lenvatinib administration was more likely to adversely affect liver function in older patients; dose adjustment should be considered in such patients.
- | lenvatinib / Generic mfg.
Preclinical, Journal: A novel heat shock protein inhibitor KU757 with efficacy in lenvatinib-resistant follicular thyroid cancer cells overcomes up-regulated glycolysis in drug-resistant cells in vitro. (Pubmed Central) - Apr 27, 2021
Lenvatinib administration was more likely to adversely affect liver function in older patients; dose adjustment should be considered in such patients. Lenvatinib resistance leads to increased glycolysis, and KU757 effectively treats lenvatinib-resistant cells and overcomes this increased glycolysis by targeting key glycolytic genes, proteins, and long non-coding ribonucleic acids.
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion, Trial completion date, Metastases: EPOC1706: Lenvatinib and Pembrolizumab Simultaneous Combination Study (clinicaltrials.gov) - Apr 26, 2021
P2, N=29, Completed, Sponsor: National Cancer Center Hospital East
Lenvatinib resistance leads to increased glycolysis, and KU757 effectively treats lenvatinib-resistant cells and overcomes this increased glycolysis by targeting key glycolytic genes, proteins, and long non-coding ribonucleic acids. Active, not recruiting --> Completed | Trial completion date: Sep 2022 --> Apr 2021
- |||||| Enrollment open, Metastases: A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) (clinicaltrials.gov) - Apr 25, 2021
P3, N=1431, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed | Trial completion date: Sep 2022 --> Apr 2021 Not yet recruiting --> Recruiting